TY -的T1 -以病人为中心的结果JF -神经学乔-神经病学SP - S24 LP - -首页 10.1212 / WNL S35做。0 b013e3181dbb884六世- 74 - 17补充3 AU -黛博拉·米勒AU - Richard a . Rudick AU -迈克尔·哈钦森Y1 - 2010/04/27 UR - //www.ez-admanager.com/content/74/17_Suppleme首页nt_3/S24.abstract N2 -背景:多发性硬化症(MS)是一种神经退行性疾病与健康相关的生活质量显著障碍(HRQoL)。虽然标准临床终点如扩大残疾状态规模和年复发率仍有用女士在评估活动和严重程度,这些措施并不完全反映疾病的病人的经验。女士在就业状况的影响,社会和家庭关系,性满意度、疼痛、疲劳、享受生活,视野,膀胱和肠道控制,认知,情绪可以是深远的,可能影响病人坚持长期治疗。通用HRQoL工具,如医疗结果短Form-36和功能状况问卷调查最初被用于研究女士。然而,MS-specific和混合工具,现在拥有更大的敏感性已经开发出来。临床专家意见:β干扰素对HRQoL的影响已经在几项研究,评估和改进HRQoL的一些尺寸,特别是在患者轻度残疾,已报告。两大关键研究natalizumab前瞻性包括HRQoL评估三级疗效终点。natalizumab HRQoL结果的影响患者的复发缓和女士很明显在持续两年无论疾病进展或复发的地位。未来发展方向:以病人为中心的结果在评估治疗女士正变得越来越重要。 Therefore, inclusion of HRQoL assessments in pivotal clinical studies eventually should become standard practice. Increasing our understanding of minimally important clinical change in these measures will be an important step in helping researchers and clinicians interpret these results beyond statistical significance. DMT=disease-modifying therapy; EDSS=Expanded Disability Status Scale; FAMS=Functional Assessment of Multiple Sclerosis; FSQ=Functional Status Questionnaire; GA=glatiramer acetate; HRQoL=health-related quality of life; IFN=interferon; IM=intramuscular; LMSQoL=Leeds Multiple Sclerosis Quality of Life scale; MCS=Mental Component Summary; MOS=Medical Outcomes Study; MS=multiple sclerosis; MSCRG=Multiple Sclerosis Collaborative Research Group; MSIS=Multiple Sclerosis Impact Scale; MSQLI=Multiple Sclerosis Quality of Life Inventory; MSQoL=Multiple Sclerosis Quality of Life instrument; PCS=Physical Component Summary; PES=Pain Effects Scale; RRMS=relapsing-remitting MS; SC=subcutaneous; SF-36=Short Form-36; SIP=Sickness Impact Profile; SPMS=secondary progressive MS. ER -